Arthneeti

Bliss GVS Pharma Share Price & Earnings Call Analysis

₹631.30+2.28% today
Market cap
₹6,716 Cr
P/E
41.30
ROE
11.75%
PEG
1.78
Price to sales
6.25
Debt to equity
0.02
52W high / low
₹738 / ₹128
Sales growth (5Y)
9.94%
EBITDA margin
21.99%
Net profit margin
14.83%
Promoter holding
50.07%
Sales (last year)
₹1,074 Cr

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Bliss GVS Pharma rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Bliss GVS Pharma announcements

All announcements →

Financials of Bliss GVS Pharma

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Bliss GVS Pharma

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +34.97%34.97%34.90%34.82%35.10%35.29%35.44%35.39%35.36%35.36%35.01%50.07%
FIIs +15.35%14.74%13.24%12.13%13.51%13.18%12.65%13.27%14.54%10.45%8.07%5.03%
DIIs +6.60%6.59%6.58%6.56%6.55%6.55%6.54%5.98%5.78%5.04%9.46%9.62%
Public +43.08%43.71%45.27%46.49%44.84%44.98%45.37%45.36%44.32%49.15%47.45%35.29%
No. of Shareholders40,75845,15744,73752,93749,55849,51746,70744,46143,38044,87446,76747,944

Financials of Bliss GVS Pharma

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +212201198184218210198207244218257286313
YoY Sales growth+23%-2%+7%+15%+3%+5%-0%+13%+12%+4%+30%+38%+28%
Expenses +158157170149176181177166201183213209233
Operating Profit54442834413021414335447681
OPM %26%22%14%19%19%14%11%20%18%16%17%27%26%
Other Income +135-244515123581611108
Interest1222412531213
Depreciation677778888891010
Profit before tax5940-430363623634141457575
Tax %27%27%24%26%28%29%29%30%30%39%18%32%29%
Net Profit +4329-522262617442925375153
EPS in Rs4.052.64-0.871.972.312.261.474.082.582.203.364.724.91

Financials of Bliss GVS Pharma

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +4075477988158996895777477527708109271,074
Sales growth+18%+34%+46%+2%+10%-23%-16%+29%+1%+2%+5%+14%+25%
Expenses +304391596618739566471629634620683760838
Operating Profit103156203197160123107118117151127168236
OPM %25%29%25%24%18%18%18%16%16%20%16%18%22%
Other Income +202412-8352620-4218-0366745
Interest1619202348651078127
Depreciation1113202191317171926293337
Profit before tax9614817514518212910454106117126190236
Tax %36%32%36%39%30%26%29%57%28%30%28%29%
Net Profit +6110011389127957423778290135166
EPS in Rs5.818.007.955.7011.999.436.641.456.807.218.0012.2115.19
Dividend Payout %12%6%8%18%8%5%8%34%7%7%6%4%

Financials of Bliss GVS Pharma

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital10101010101010101010111111
Reserves3274024765266367257988088739571,0401,1821,280
Borrowings +160132225118102126122109102100882223
Other Liabilities +166218311206157168147181171145163278269
Total Liabilities6627621,0238609051,0301,0771,1091,1571,2121,3011,4921,582
Fixed Assets +234225305143146242234281379370406459471
CWIP0940470222382168
Investments0000000284454
Other Assets +4285277147177127888408037688308711,0221,100
Total Assets6627621,0238609051,0301,0771,1091,1571,2121,3011,4921,582

Financials of Bliss GVS Pharma

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +381132891840476413534103106139
Cash from Investing Activity +-29-50-24948-79-40-45-103-6-83-75-38
Cash from Financing Activity +-42-40-10-7617-6-21-24-25-21-30-89
Net Cash Flow-342330-10-220-293-1011
Free Cash Flow5101186-72-125563-59753384
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit45%101%160%29%-8%69%87%143%67%91%112%108%

Financials of Bliss GVS Pharma

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days222201116134187290293192187192198204
Inventory Days69555055466411011694113111129
Days Payable165153100554775828679586389
Cash Conversion Cycle12610267134186279321221202247246244
Working Capital Days10584-10135154232264179192207198214
ROCE %23%31%29%27%26%18%12%14%12%14%12%17%
98out of 100

Momentum score · price trend

98 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+293.5%99%
Last 6 months+125.2%98%
Last 3 months+32.3%94%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Bliss GVS Pharma: 0.4 × 99 + 0.4 × 98 + 0.2 × 94 = 98.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.